retatrutide phase 2 study results Safety, Side Effects & Provider Use ESC 2024: Retatrutide improves lipid

The JPMLs order came after at least 18 GLP1 lawsuits have been filed in various different federal district courts nationwide, each raising nearly identical allegations that drug makers rushed to get their GLP-1 drugs onto the market amid a rapid increase in popularity without first adequately researching the full safety profile and side effects

,

Retatrutide is a triple-hormone receptor agonist from Eli Lilly that produced 2428% average weight loss in Phase 2 trials, significantly exceeding the 1215% typical of semaglutide and the 1522% of tirzepatide

Potential muscle preservation

Semaglutide was approved in 2022 for use alongside lifestyle changes in pediatric patients aged 12 or older with an initial BMI equal to or greater than the 95th percentile for their age and sex

Prospective, controlled studies are needed to clarify whether GLP-1RAs have a direct therapeutic role in HS or act primarily through effects on weight and metabolic inflammation